DeutschNewstral
Article
jdsupra.com on 2016-08-30 17:46
The Ripple Effect of the Federal Circuit’s Decision in Amgen v. Apotex on Biosimilar Litigation
Related news
- Federal Circuit Decides Amgen v. Apotex, Holds that 180-Day Notice of Commercial Marketing is Always Mandatory in Biosimilar Litigationjdsupra.com
- Fall-Out from the Federal Circuit’s Decision in Amgen v. Apotexjdsupra.com
- Apotex Accuses Amgen of Sham BPCIA Litigationjdsupra.com
- Amgen and Apotex do the Biosimilar Patent Dancejdsupra.com
- Biosimilar Litigation Updatejdsupra.com
- HUMIRA® Biosimilar Update -- Settlement in AbbVie v. Amgen Case Announced and AbbVie v. Boehringer Ingelheim Litigation Beginsjdsupra.com
- U.S. Biosimilar Litigation So Farjdsupra.com
- Court Rules that Apotex Must Give Amgen Notice Upon Biosimilar Licensurejdsupra.com
- Apotex Drops Sham Litigation Counterclaims in Neupogen and Neulasta Biosimilar Litigationjdsupra.com
- Scheduling Order Entered in Amgen v. Adello Filgrastim Biosimilar Litigationjdsupra.com
- PAmgen settles with AbbVie over Humira biosimilar litigationpacbiztimes.com
- Another Biosimilar Litigation Settlement: Amgen v. Tanvex (Filgrastim)jdsupra.com
- Amgen v. Apotex – what is the outcome when biosimilar applicants actually dance?jdsupra.com
- Amgen and Accord End Filgrastim, Pegfilgrastim Biosimilar Litigationjdsupra.com
- Apotex Prevails in Neulasta Biosimilar Litigation, Files for Cert on 180-Day Issuejdsupra.com
- Amgen and Hospira Square Off Over BPCIA Private Right of Action After Amgen v. Apotex Rulingjdsupra.com
- Fed Circuit’s “Amgen v. Apotex” Decision: Clarification of a BPCIA Riddle (Unless, of course, the Supreme Court Steps In)jdsupra.com
- Amgen Can Enforce Notice of Commercial Marketing for Epogen® Biosimilarjdsupra.com
- Humira Biosimilar Approved As Litigation Gets Goingjdsupra.com
- 2021 Biosimilar Approval and Litigation Updatejdsupra.com